

Outcomes for Type C Proximal Humerus Fractures in the Geriatric Population: Comparison of Nonoperative Treatment, Locked Plate Fixation, and Reverse Shoulder Arthroplasty

Steven Samborski, MD; Brittany Haws, MD; Steven Karnyski, MD; Kyle T. Judd, MD; Catherine A. Humphrey, MD; Gillian Soles, MD; John T. Gorczyca, MD; Ilya Voloshin, MD; Gregg T. Nicandri, MD; John P. Ketz, MD
 University of Rochester, Rochester, NY, United States

Purpose: This study compares patient-reported outcomes (PROs) and range of motion (ROM) between patients managed nonoperatively, with open reduction and internal fixation (ORIF), and with reverse shoulder arthroplasty (RSA).

Methods: This was a retrospective cohort study of patients >55 years old treated with nonoperative management, ORIF, or RSA for AO/OTA Type 11C proximal humerus fractures from 2015 to 2018. Visual analog scale (VAS) pain scores, Patient-Reported Outcomes Measurement Information System (PROMIS) scores, ROM values, and complication and reoperation rates were compared using analysis of variance for continuous variables and χ^2 analysis for categorical variables.

Results: A total of 94 patients were included: 46 nonoperative, 24 ORIF, and 24 RSA. No significant differences in patient characteristics were identified ($P>0.05$). All results are reported in Table 1. At 2-week follow-up ORIF and RSA showed lower VAS scores, and better ROM and PROMIS scores ($P<0.05$) compared to nonoperative treatment. At 6-week follow-up, ORIF and RSA had lower VAS scores, and better ROM and PROMIS scores ($P<0.05$) compared to nonoperative treatment. At 3-month follow-up ORIF and RSA showed decreased VAS scores, and better ROM and PROMIS scores ($P<0.05$) compared to nonoperative treatment. At 6-month follow-up ORIF and RSA showed similar VAS scores ($P>0.05$), but better ROM and PROMIS scores ($P<0.05$) compared to nonoperative treatment. The RSA group had a significantly lower reoperation rate ($P<0.05$).

Conclusion: The management of geriatric AO/OTA type 11C proximal humerus fractures with RSA or ORIF led to early decreased pain, and improved physical function and ROM compared to nonoperative management.

Table 1. Outcomes Type C Fractures*

	Nonoperative (N=46)	ORIF (N=24)	RSA (N=24)	†p-value
Complications (n)	80.4% (37)	54.2% (13)	0.0% (0)	<0.001
Varus Malunion	54.4% (25)	37.5% (9)	--	0.181
Nonunion	4.4% (2)	4.2% (1)	--	--
HS Translation	2.2% (1)	4.2% (1)	--	--
AVN	4.4% (2)	12.5% (3)	--	--
Reoperation (n)	4.4% (2)	33.3% (8)	0.0% (0)	<0.001
Range of Motion (Mean ± SD, °)				
Active Forward Flexion				
2-week follow up	0 ± 0	0 ± 0	0 ± 0	--
6-week follow up	16.4 ± 28.1	32.6 ± 31.8	57.1 ± 50.8	<0.001
3-month follow up	56.4 ± 47.0	80.6 ± 41.1	126.1 ± 20.4	<0.001
6-month follow up	93.6 ± 29.9	104.0 ± 28.2	133.0 ± 22.5	<0.001
Passive Forward Flexion				
2-week follow up	0 ± 0	11.7 ± 28.6	46.5 ± 47.7	<0.001
6-week follow up	48.4 ± 40.8	59.9 ± 41.5	114.1 ± 31.5	<0.001
3-month follow up	68.7 ± 53.4	100.4 ± 46.5	137.5 ± 21.2	<0.001
6-month follow up	117.1 ± 22.4	126.4 ± 14.8	147.9 ± 16.1	<0.001
External Rotation				
2-week follow up	0 ± 0	0.5 ± 1.5	3.3 ± 6.1	<0.001
6-week follow up	12.3 ± 14.7	14.7 ± 14.5	23.4 ± 13.8	0.005
3-month follow up	22.3 ± 23.4	29.1 ± 21.8	37.3 ± 21.3	0.013
6-month follow up	36.6 ± 20.0	35.9 ± 20.7	44.1 ± 19.4	0.233
Patient Reported Outcomes (Mean ± SD)				
VAS Pain Score				
2-week follow up	6.2 ± 3.3	2.6 ± 2.4	2.7 ± 2.6	<0.001
6-week follow up	3.7 ± 3.0	2.1 ± 2.4	1.1 ± 1.7	<0.001
3-month follow up	2.4 ± 2.6	1.8 ± 2.1	1.1 ± 2.0	0.047
6-month follow up	1.8 ± 2.4	1.5 ± 2.3	0.8 ± 1.6	0.085
PROMIS Depression				
2-week follow up	58.3 ± 8.9	54.0 ± 9.6	55.8 ± 7.0	0.285
6-week follow up	53.1 ± 9.4	52.7 ± 8.1	52.8 ± 7.3	0.882
3-month follow up	51.3 ± 8.7	48.8 ± 8.5	49.3 ± 10.2	0.409
6-month follow up	52.5 ± 11.2	47.2 ± 11.3	46.8 ± 10.6	0.117
PROMIS Pain Interference				
2-week follow up	69.9 ± 6.3	64.5 ± 7.2	63.8 ± 6.9	0.003
6-week follow up	61.5 ± 5.9	58.1 ± 5.3	57.4 ± 5.7	0.012
3-month follow up	60.0 ± 6.2	58.8 ± 6.7	50.0 ± 7.3	<0.001
6-month follow up	58.9 ± 9.6	53.5 ± 8.0	53.3 ± 6.0	0.042
PROMIS Physical Function				
2-week follow up	28.1 ± 6.7	31.0 ± 5.9	28.3 ± 4.8	0.765
6-week follow up	30.6 ± 4.7	35.8 ± 5.3	33.8 ± 4.4	0.016
3-month follow up	35.4 ± 8.5	40.4 ± 5.7	39.0 ± 4.3	0.076
6-month follow up	36.7 ± 8.9	44.3 ± 5.6	42.2 ± 5.2	0.021

SD = Standard deviation; ORIF = Open reduction internal fixation; RSA = Reverse shoulder arthroplasty; HS = Head-Inaft; AVN = Avascular necrosis; VAS = Visual analog scale; PROMIS = Patient reported outcomes measurement information system.
 *Boldface indicates statistical significance.
 †p-values calculated using analysis of variance and chi square analysis for continuous and categorical variables, respectively.
 ‡Additional complications: Nonoperative – valgus malunion (9); ORIF – screw cutout (2), hardware failure (2), adhesive capsulitis (1), symptomatic hardware (1).
 § Reoperations: Nonoperative – conversion to arthroplasty (2); ORIF – conversion to arthroplasty (3), revision fixation (2), removal of hardware (2), lysis of adhesions (1).

The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device he or she wishes to use in clinical practice.